Atria Investments Inc Boosts Holdings in Insmed Incorporated (NASDAQ:INSM)

Atria Investments Inc boosted its position in shares of Insmed Incorporated (NASDAQ:INSM) by 5.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,232 shares of the biopharmaceutical company’s stock after acquiring an additional 247 shares during the period. Atria Investments Inc’s holdings in Insmed were worth $361,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of INSM. Vestal Point Capital LP lifted its position in Insmed by 113.3% during the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after acquiring an additional 850,000 shares during the last quarter. Victory Capital Management Inc. increased its stake in Insmed by 209.9% during the 3rd quarter. Victory Capital Management Inc. now owns 455,959 shares of the biopharmaceutical company’s stock valued at $33,285,000 after purchasing an additional 308,819 shares in the last quarter. Westfield Capital Management Co. LP acquired a new position in Insmed during the 3rd quarter valued at approximately $18,377,000. Eventide Asset Management LLC increased its stake in Insmed by 34.2% during the 3rd quarter. Eventide Asset Management LLC now owns 906,395 shares of the biopharmaceutical company’s stock valued at $66,167,000 after purchasing an additional 231,210 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in Insmed by 12.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock valued at $136,648,000 after purchasing an additional 214,130 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts have issued reports on INSM shares. JPMorgan Chase & Co. upped their price target on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday, February 7th. Guggenheim restated a “buy” rating and set a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. Royal Bank of Canada initiated coverage on shares of Insmed in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $100.00 price objective on the stock. Morgan Stanley increased their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

Insmed Price Performance

Shares of INSM opened at $76.55 on Monday. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The stock has a market cap of $13.86 billion, a PE ratio of -13.69 and a beta of 1.28. The firm has a 50-day simple moving average of $76.17 and a two-hundred day simple moving average of $73.69. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. As a group, analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Activity at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of Insmed stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the completion of the transaction, the insider now owns 97,083 shares in the company, valued at $7,766,640. The trade was a 48.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the sale, the chief executive officer now owns 384,960 shares of the company’s stock, valued at $26,885,606.40. This represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 550,957 shares of company stock worth $42,859,028. Corporate insiders own 4.60% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.